Becton Dickinson and Co vs FMC Corp — how do they compare? Becton Dickinson and Co trades at $179.81 (market cap $49.41B), while FMC Corp trades at $10.19 (market cap $1.30B). The key difference: Becton Dickinson and Co is far larger — about 38× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| BDX | FMC | |
|---|---|---|
Market Cap | $49.41B | $1.30B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $40.69 |
52-Week Low | $138.62 | $10.01 |
Enterprise Value | $65.51B | $5.11B |
Dividend Yield | 2.32% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
FMC stock trades at $10.46, down 1.23% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profitability margins, though recent quarters show mixed earnings beats. Analyst consensus is divided, with a $11.60 price target, while recent news highlights revenue challenges and strategic moves like a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and weak revenue trends, but debt reduction efforts and cost controls offer some stability. Key risks include competitive pressures and macroeconomic headwinds, while the current valuation metrics like P/S of 0.4 may attract value investors if operational improvements materialize.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →